David Rimm, MD, PhD, discusses the key takeaways from the results of a phase I/II trial presented in a poster at the 2019 San Antonio Breast Cancer Symposium, which evaluated neoadjuvant checkpoint inhibition in a small subset of patients with triple-negative breast cancer.<br />
David Rimm, MD, PhD, a pathologist at Yale University School of Medicine and professor in the Department of Pathology and Department of Medical Oncology, discusses the key takeaways from the results of a phase I/II trial presented in a poster at the 2019 San Antonio Breast Cancer Symposium, which evaluated neoadjuvant checkpoint inhibition in a small subset of patients with triple-negative breast cancer (TNBC).
A durvalumab (Imfinzi)-based regimen improved outcomes in patients with TNBC compared with chemotherapy alone. These findings were consistent with those of KEYNOTE-522, which evaluated the checkpoint inhibitor pembrolizumab (Keytruda) in a larger population. However, this small trial compared the antibody to PD-L1 ligand as opposed to in comparison with the PD-1 receptor in KEYNOTE-522, says Rimm.
Breast Cancer Leans into the Decade of Antibody-Drug Conjugates, Experts Discuss
September 25th 2020In season 1, episode 3 of Targeted Talks, the importance of precision medicine in breast cancer, and how that vitally differs in community oncology compared with academic settings, is the topic of discussion.
Listen
Rugo Surveys Peers on Treatment After Metastatic Relapse of HR+, HER2– Breast Cancer
April 20th 2024During a Case-Based Roundtable® event, Hope S. Rugo, MD, FASCO, moderated a discussion on treatment options for a patient whose breast cancer recurred several years after adjuvant therapy.
Read More